BridgeMD
New treatment option for Clinical High Risk for Psychosis (CHR)
Official title French Validation of Schizophrenia Proneness Instrument- Child Youth
ClinicalTrials.gov ID: NCT06649552
What this study is testing
- What it's testing
- The clinical concept of a at risk mental state of developing psychosis is based on the identification of attenuated psychotic symptoms during the prodromal phase of psychoses (Schmidt et al., 2015). Early detection and support of these symptoms can delay the risk of transition to a first psychotic episode (van der Gaag, van den Berg, \& Ising, 2019).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 17
You may be able to join if
- Patients (men or women) followed at one of the 3 following structures in France : CLIP-Ado Nancy, CH Alpes-Isère, CHRU Lille for a suspected mental...
- Age between 12 and 17 years and 11 months
- Affiliation with a social security scheme or beneficiary of such a scheme.
- Native language: French.
- Adolescents who have been informed of the study, have received the study information note and have not objected to participating in the study
You likely can't join if
- Pregnant woman, parturient or nursing mother
- Person deprived of liberty by judicial or administrative decision
- Person in a life-threatening emergency
- Impairment of the subject that makes it difficult, if not impossible, to participate in the trial or to understand the information provided.
- Abuse or dependence on any substance according to DSM V criteria, excluding cannabis
See the full eligibility criteria
- Patients (men or women) followed at one of the 3 following structures in France : CLIP-Ado Nancy, CH Alpes-Isère, CHRU Lille for a suspected mental state at risk of developing psychosis, as determined by the CAARMS...
- Age between 12 and 17 years and 11 months
- Affiliation with a social security scheme or beneficiary of such a scheme.
- Native language: French.
- Adolescents who have been informed of the study, have received the study information note and have not objected to participating in the study
- At least one of the holders of parental authority having been informed of the study, having received the relevant information note and not having objected to the adolescent participation
- Consent to audio recording of the SPI-CY scale administration: for the adolescent and at least one parent.
- Pregnant woman, parturient or nursing mother
- Person deprived of liberty by judicial or administrative decision
- Person in a life-threatening emergency
- Impairment of the subject that makes it difficult, if not impossible, to participate in the trial or to understand the information provided.
- Abuse or dependence on any substance according to DSM V criteria, excluding cannabis
The study team makes the final eligibility decision.
Where it's taking place
- Lille, France
- Nancy, France
- Saint-Egrève, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lille, France; Nancy, France; Saint-Egrève, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.